Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics (SGMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 514,306
  • Shares Outstanding, K 208,221
  • Annual Sales, $ 176,230 K
  • Annual Income, $ -257,830 K
  • EBIT $ -257 M
  • EBITDA $ -148 M
  • 60-Month Beta 1.10
  • Price/Sales 2.55
  • Price/Cash Flow 58.66
  • Price/Book 18.92

Options Overview Details

View History
  • Implied Volatility 156.40% ( +1.28%)
  • Historical Volatility 167.51%
  • IV Percentile 24%
  • IV Rank 9.08%
  • IV High 1,058.08% on 11/14/23
  • IV Low 66.32% on 05/08/24
  • Put/Call Vol Ratio 0.38
  • Today's Volume 15,193
  • Volume Avg (30-Day) 7,188
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 94,643
  • Open Int (30-Day) 65,619

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.07
  • Number of Estimates 3
  • High Estimate 0.02
  • Low Estimate -0.14
  • Prior Year -0.34
  • Growth Rate Est. (year over year) +79.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.77 +273.22%
on 10/10/24
2.97 -2.86%
on 11/07/24
+2.08 (+259.64%)
since 10/07/24
3-Month
0.70 +312.14%
on 09/09/24
2.97 -2.86%
on 11/07/24
+2.03 (+236.68%)
since 08/07/24
52-Week
0.29 +891.07%
on 11/13/23
2.97 -2.86%
on 11/07/24
+2.46 (+586.90%)
since 11/07/23

Most Recent Stories

More News
3 Penny Stocks With 66% to 245% Upside Potential

Investing in these penny stocks could unlock extraordinary gains, with expected returns of up to 245%. Here are three analyst-recommended stocks from in-demand industries, all with significant upside potential....

AAPL : 227.49 (+2.14%)
AMZN : 210.16 (+1.48%)
LUNR : 9.52 (+15.25%)
SGMO : 2.81 (+13.77%)
SVM : 4.59 (+3.38%)
$SPX : 5,973.10 (+0.74%)
PFE : 27.46 (+0.37%)
SIU24 : 32.025s (+1.03%)
GCZ24 : 2,713.3 (+1.38%)
Sangamo: Q2 Earnings Snapshot

Sangamo: Q2 Earnings Snapshot

SGMO : 2.81 (+13.77%)
Sangamo: Q1 Earnings Snapshot

Sangamo: Q1 Earnings Snapshot

SGMO : 2.81 (+13.77%)
Sangamo: Q4 Earnings Snapshot

Sangamo: Q4 Earnings Snapshot

SGMO : 2.81 (+13.77%)
Sangamo: Q3 Earnings Snapshot

Sangamo: Q3 Earnings Snapshot

SGMO : 2.81 (+13.77%)
Sangamo: Q2 Earnings Snapshot

Sangamo: Q2 Earnings Snapshot

SGMO : 2.81 (+13.77%)
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for presentation at the...

SGMO : 2.81 (+13.77%)
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including a strategic pipeline prioritization and restructuring, and reported certain...

SGMO : 2.81 (+13.77%)
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its first quarter 2023 financial results after the market closes on Wednesday,...

SGMO : 2.81 (+13.77%)
Sangamo: Q4 Earnings Snapshot

Sangamo: Q4 Earnings Snapshot

SGMO : 2.81 (+13.77%)

Business Summary

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 3.29
2nd Resistance Point 2.92
1st Resistance Point 2.70
Last Price 2.81
1st Support Level 2.10
2nd Support Level 1.73
3rd Support Level 1.51

See More

52-Week High 2.97
Last Price 2.81
Fibonacci 61.8% 1.95
Fibonacci 50% 1.63
Fibonacci 38.2% 1.31
52-Week Low 0.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar